NCT02589275View on ClinicalTrials.gov

A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients

PHASE3CompletedINTERVENTIONAL

Enrollment

375

Participants

Timeline

Start Date

August 4, 2015

Primary Completion Date

September 28, 2016

Study Completion Date

September 28, 2016

Conditions

Primary Fibromyalgia

Interventions

DRUG

TNX-102 SL Tablet 2.8 mg

TNX-102 SL 2.8 mg tablet taken daily at bedtime

Trial Locations (33)

14221

Williamsville

18104

Allentown

22911

Charlottesville

23507

Norfolk

29464

Mt. Pleasant

29650

Greer

30080

Smyrna

31904

Columbus

32720

DeLand

32806

Orlando

33409

West Palm Beach

33511

Brandon

33614

Tampa

33805

Lakeland

34471

Ocala

35216

Birmingham

39202

Jackson

44130

Middleburg Heights

45206

Cincinnati

47714

Evansville

48104

Ann Arbor

53142

Kenosha

75231

Dallas

84102

Salt Lake City

85032

Phoenix

92103

San Diego

95825

Sacramento

97210

Portland

97504

Medford

98007

Bellevue

98104

Seattle

02747

North Dartmouth

02888

Warwick

All Listed Sponsors

lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT02589275 - A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients | Biotech Hunter | Biotech Hunter